Siemens Healthineers (XTRA:SHL) Eyes MRI Growth, Is The Stock Still Cheap?

MarketsandMarkets now expects the global MRI systems market to expand, and Siemens Healthineers (XTRA:SHL) sits directly in that conversation as it spends heavily on helium-free and AI-assisted scanners.

Siemens Healthineers’ share price tells a mixed story, with the stock down 13.39% on a year to date basis and the 1-year total shareholder return declining 17.79%, even as a 10.40% 90-day share price gain suggests some momentum is starting to rebuild around its MRI and broader imaging push.

Scan for other Siemens Healthineers style plays in medical imaging and AI diagnostics by reviewing the hand picked 131 healthcare AI stocks.

The share price has bounced, yet Siemens Healthineers still trades well below both analyst targets and some intrinsic value estimates. Is this a recovery already priced fairly, or a gap that still looks wide?

Most Popular Narrative: 16.3% Undervalued

On the most followed narrative, Siemens Healthineers screens as undervalued, with a fair value of €45.65 against a last close of €38.23, and that gap leans heavily on earnings power and margin expectations over the next few years.

A rapidly aging population and rising chronic disease incidence are consistently boosting demand for high-precision diagnostics and individualized therapies, which are core competencies for Siemens Healthineers and indicate a durable multi-year uplift in addressable market size and likely top-line growth.

Read the complete narrative.

Want to see what keeps that fair value above today’s price? The narrative leans on steady revenue expansion, thicker margins, and a richer future earnings multiple. The exact mix of those levers is where the story gets interesting.

Result: Fair Value of €45.65 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, tariff pressure in Imaging and Advanced Therapies and ongoing restructuring in Diagnostics could affect Siemens Healthineers’ margins and unsettle that undervaluation story.

Find out about the key risks to this Siemens Healthineers narrative.

Next Steps

This mix of optimism and concern around Siemens Healthineers will not stay static for long. Review the data, stress test the assumptions, and weigh the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Siemens Healthineers?

If you only focus on Siemens Healthineers, you could miss other opportunities that fit your style even better, so consider putting a few fresh contenders on your radar.

• Target reliable compounding potential by reviewing a curated mix of quality undervalued candidates through the 184 high quality undervalued stocks.
• Strengthen your downside protection by using a 97 resilient stocks with low risk scores that screens for resilience when conditions turn difficult.
• Explore potential opportunities by checking a 621 high quality undiscovered gems that highlights lesser known businesses with strong underlying fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com